- Webcast and Conference Call to Be Held Thursday, November 8, 9:00
a.m. EST -
WALTHAM, Mass.--(BUSINESS WIRE)--
Repligen Corporation (NASDAQ:RGEN) today announced that it will report
financial results for the third quarter of 2012 before the NASDAQ Global
Market opens on Thursday, November 8. The earnings press release will be
followed by a conference call and webcast at 9:00 a.m. EST. The event
will be hosted by Walter C. Herlihy, Ph.D., President and CEO of
Repligen, who will discuss financial results for the third quarter and
year-to-date and provide a corporate update.
Repligen’s third quarter conference call will be accessible by dialing (800)
260-8140 for domestic callers or (617) 614-3672 for
international callers. Dial-in participants must provide the passcode 85324503.
Alternatively, an audio webcast will be accessible via the Investors
section of Repligen’s website www.repligen.com.
Both the conference call and webcast will be archived for a period of
time following the live event. The replay dial-in numbers are (888)
286-8010 for domestic callers and (617) 801-6888 for international
callers. Replay listeners must provide the passcode 97138968.
About Repligen Corporation
Repligen Corporation is a life sciences company focused on the
development, production and commercialization of products used in the
process of manufacturing biological drugs. Our bioprocessing products
are sold to major life sciences and biopharmaceutical companies
worldwide. We are a leading manufacturer of Protein A, a critical
reagent used to manufacture monoclonal antibody-based therapeutics. We
also supply several growth factor products used to increase cell culture
productivity in biomanufacturing. In the burgeoning area of disposable
biomanufacturing technologies, we have developed and market a series of
OPUS® (Open Platform User Specified) single-use
chromatography columns used in the biologics purification process. In
addition to our core bioprocessing business, we have a portfolio of
clinical-stage partnering assets, including two central nervous system
orphan drug candidates and a pancreatic imaging agent in Phase 3
development. Repligen’s corporate headquarters are located in Waltham,
MA, USA, with an additional manufacturing facility in Lund, Sweden. For
more information, please visit our website at www.repligen.com.
This press release may contain forward-looking statements within the
meaning of the federal securities laws. Investors are cautioned that
statements in this press release which are not strictly historical
statements including, without limitation, statements identified by words
like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could”
and similar expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from
those anticipated, including, risks discussed from time to time in our
filings with the Securities and Exchange Commission. We expressly
disclaim any responsibility to update forward-looking statements, except
as required by law.
Repligen Corporation
Sondra Newman, 781-419-1881
Director
Investor Relations
snewman@repligen.com
Source: Repligen Corporation